JulieMPaikMD

Physician

Dr. Paik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Brigham Womens Hospital
75 Francis St Renal Div MRB4
Boston, MA 02115
Phone+1 617-732-6383

Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 2007 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2004 - 2007
Icahn School of Medicine at Mount SinaiClass of 2004

PubMed

21 citations
Accuracy of GFR Estimating Equations in Patients with Discordances between Creatinine and Cystatin C-Based Estimations.
Edouard L Fu, Andrew S Levey, Josef Coresh, Carl-Gustaf Elinder, Joris I Rotmans
Journal of the American Society of Nephrology. 2023-07-01
9 citations
Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.
Edouard L Fu, Elvira D'Andrea, Deborah J Wexler, Elisabetta Patorno, Julie M Paik
Clinical Journal of the American Society of Nephrology. 2023-05-01
54 citations
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.
Arnaud D Kaze, Min Zhuo, Seoyoung C Kim, Elisabetta Patorno, Julie M Paik
Cardiovascular Diabetology. 2022-03-23

SGLT2 Inhibitors vs DPP4 Inhibitors Lower Hyperkalemia Risk in CKD+T2D CasesAugust 15th, 2024
Empagliflozin May Reduce Stone RiskNovember 5th, 2022
SGLT2 Inhibitor Use Rising in Patients with DKDAugust 23rd, 2021
Join now to see all